← Back to Calendar

Relay Therapeutics Q1 2026 Earnings

Relay Therapeutics · $RLAY

Standard Review Earnings

PDUFA Date

May 7, 2026

Time Remaining

44 days

Review Type

Standard (10 mo)

Indication

Q1 2026 earnings + zovegalisib SERENA-PI3K data update

Key Notes

Q1 2026 earnings expected ~May 2026. Expected to include Phase 2 data update from SERENA-PI3K trial — key readout before or at ASCO 2026 (May 29). Update on breast cancer triplet data and frontline Phase 3 timeline.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar